目的 探討康艾注射液聯(lián)合注射用鹽酸吉西他濱治療非小細(xì)胞肺癌的臨床療效。方法 選取西安交通大學(xué)醫(yī)學(xué)院第一附屬醫(yī)院2013年1月—2015年1月就診的非小細(xì)胞肺癌患者100例，將患者隨機(jī)分為對照組和治療組，每組各50例。對照組給予注射用鹽酸吉西他濱1200 mg/m²，加入100 mL生理鹽水中，第1、8天靜脈滴注。治療組在對照組基礎(chǔ)上靜脈滴注康艾注射液50 mL/m²，加入250 mL生理鹽水中，連續(xù)使用14 d。兩組均連續(xù)治療21 d。觀察兩組的臨床療效，同時(shí)比較治療前后兩組患者的免疫功能指標(biāo)、蛋白表達(dá)和毒副反應(yīng)。結(jié)果 治療后，對照組、治療組的客觀有效率分別為48.0%、66.0%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組疾病控制率比較差異無顯著性。治療后，兩組CD⁴⁺、CD⁴⁺/CD⁸⁺明顯上升，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組CD3+、CD⁴⁺、CD⁴⁺/CD⁸⁺明顯上升，CD⁸⁺明顯下降，其改善程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組Ki67蛋白、bcl-2蛋白表達(dá)水平明顯降低，bax蛋白表達(dá)水平明顯升高，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組血小板減少、白細(xì)胞下降、紅細(xì)胞減少發(fā)生率明顯低于對照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。但兩組ALT異常升高、惡心嘔吐的發(fā)生率比較差異無統(tǒng)計(jì)學(xué)意義。結(jié)論 康艾注射液聯(lián)合注射用鹽酸吉西他濱治療非小細(xì)胞肺癌具有較好的臨床療效，能夠增強(qiáng)患者免疫功能，改善蛋白表達(dá)，降低毒副反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the effects of Kang'ai Injection combined with Gemcitabine Hydrochloride for injection in treatment of non-small cell lung cancer. Methods Patients (100 cases) with non-small cell lung cancer in the First Affiliated Hospital of Xi'an Jiao Tong University Medical College from January 2013 to January 2015 were randomly divided into the control and treatment groups, and each group had 50 cases. Patients in the control group were iv administered with Gemcitabine Hydrochloride for injection of 1200 mg/m², added into normal saline 100 mL, given on days 1 and 8. The patients in treatment group were iv administered with Kang'ai Injection on the basis of control group, 50 mL/m² Kang'ai Injection added into normal saline 250 mL, and treated for 14 d. The patients in two groups were treated for 21 d. After treatment, the clinical efficacies were evaluated, and immune function indexes, protein expression, and side effect in two groups were compared before and after treatment. Results After treatment, objective response rate (ORR) in the control group and treatment group were 48.0% and 66.0%, respectively, and there were differences between two groups (P<0.05). But there were no differences on disease control rates (DCR) between two groups. After treatment, CD⁴⁺ and CD⁴⁺/CD⁸⁺ in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, CD3+, CD⁴⁺, and CD⁴⁺/CD⁸⁺ in the treatment group were significantly increased, CD⁸⁺ was significantly decreased, the observational indexes were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, protein expression of Ki67 and bcl-2 in two groups was significantly decreased, protein expression of bax was significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the incidence rates of thrombocytopenia, leucopenia, and oligocythemia in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P<0.05). But there were no differences on incidence of ALT abnormalities and nausea and vomiting between two groups. Conclusion Kang'ai Injection combined with Gemcitabine Hydrochloride for injection has clinical curative in treatment of non-small cell lung cancer, can significantly improve the immune function, and improve protein expression, reduce the adverse reactions of chemotherapy, which has a certain clinical application value.